Shares of biopharmaceutical company IMMP skyrocketed 97% in early trading Thursday after the U.S. Food and Drug Administration granted orphan drug designation to its experimental therapy efti for treating a rare form of cancer. The designation provides financial incentives and market exclusivity to encourage development of treatments for rare diseases affecting fewer than 200,000 Americans.
Efti, also known as eftilagimod alpha, is a soluble LAG-3 protein being developed as an immunotherapy for metastatic breast cancer. Analysts note the orphan drug status could accelerate the drug’s development timeline and improve its commercial potential. ‘This is a significant milestone that validates the science behind efti,’ said a biotech analyst who requested anonymity due to company policy.
The FDA’s orphan drug program offers seven years of market exclusivity, tax credits for clinical trials, and waived FDA application fees. IMMP’s CEO stated in a press release that the designation ‘reinforces our commitment to addressing unmet medical needs in oncology.’
Market observers caution that while orphan drug status is positive, efti still faces rigorous clinical testing. Phase 2b trial results are expected in Q4 2026, with analysts divided on the drug’s ultimate commercial prospects given the small patient population.